[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"illness-anxiety-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:illness-anxiety-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100431561","phase-2-study-of-dextromethorphan-in-ocd-and-related-disorders-100431561",false,"NCT04899687","Study of Dextromethorphan in OCD and Related Disorders","Fluoxetine\u002FDextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study","Inclusion Criteria:\n\n* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)\n* Living within California\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Current bipolar disorder or psychotic disorder\n* Active moderate or severe substance use disorder, lifetime severe substance use disorder\n* Pregnant or nursing women\n* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start\n* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start","ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.",[27,28,29,30],"Obsessive-Compulsive Disorder","Illness Anxiety Disorder","Body Dysmorphic Disorders","Somatic Symptom Disorder",[32,33,34,35,36,37],"OCD","BDD","IAD","SSD","Fluoxetine","Dextromethorphan","RECRUITING","2026-05-18",{"date":41,"type":42},"2026-05-20","ACTUAL",{"date":44,"type":42},"2022-01-20",{"date":46,"type":21},"2028-12-01",{"name":48,"class":49},"Stanford University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100356252","caloric-vestibular-stimulation-for-modulation-of-insight-in-obsessive-compulsive-spectrum-disorders-100356252","NCT03918577","Caloric Vestibular Stimulation for Modulation of Insight in Obsessive-Compulsive Spectrum Disorders","Inclusion Criteria:\n\n* Age 18-65\n* Primary diagnosis of Obsessive-Compulsive Disorder, Body Dysmorphic Disorder, Illness Anxiety Disorder or Somatic Symptom Disorder (excluding \"with predominant pain\")\n* Strongly held OCRD-related concerns meeting BABS score criterion.\n* No recent change in psychopharmacological treatment, if any\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Psychiatric or medical conditions (eg, vertigo, history of otological surgery) that might make participation unsafe\n* Pregnant or nursing women\n* Active or recent substance use",{"count":58,"type":21},16,[60],"NA","This study investigates whether caloric vestibular stimulation can modulate a measure of insight in obsessive-compulsive spectrum disorders.",[27,29,28],[64,65],"Caloric Vestibular Stimulation","Insight","2026-01-21",{"date":68,"type":42},"2026-01-22",{"date":70,"type":42},"2022-05-10",{"date":72,"type":21},"2026-12-30",{"name":48,"class":49},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":50},"100472117","respiratory-training-in-the-treatment-of-transdiagnostic-pathological-anxiety-100472117","NCT05427708","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).\n2. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their \"primary\" mental disorder:\n\n   * Generalized Anxiety Disorder\n   * Panic Disorder\n   * Health Anxiety\n   * Agoraphobia\n   * Social Anxiety Disorder\n   * Posttraumatic Stress Disorder\n   * Acute Stress Disorder\n   * Adjustment Disorder with primary anxious mood\n   * Anxiety disorder not otherwise specified\n3. No current use of psychotropic medications or stable on current medications for at least 6 weeks\n4. Age 18+.\n5. Able to arrange transportation to our laboratory for study appointments.\n6. Fluent in English.\n\nExclusion Criteria:\n\n1. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:\n\n   * Cardiovascular or respiratory disorders\n   * High blood pressure\n   * Epilepsy\n   * Strokes\n   * Seizures\n   * History of fainting\n   * Pregnant or lactating\n2. Not currently receiving other psychological treatment for anxiety.\n3. No history of a suicide attempt within the past 6 months.\n4. No history of psychosis within the past 6 months.\n5. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.\n6. Does not endorse COVID-19 symptoms during the screening phase.",{"count":82,"type":21},180,[60],"Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.",[86,87,88,89,90,28,91,92,93,94],"Anxiety Disorders","Trauma","Generalized Anxiety Disorder","Panic Disorder","Agoraphobia","Social Anxiety Disorder","Posttraumatic Stress Disorder","Acute Stress Disorder","Adjustment Disorder With Anxious Mood",[96,97,98,99],"Psychoeducation","Respiratory training","Transdiagnostic","Intervention","2025-08-18",{"date":102,"type":42},"2025-08-24",{"date":104,"type":42},"2022-08-22",{"date":106,"type":21},"2027-05",{"name":108,"class":49},"University of Texas at Austin"]